Jingwu Zhang Zang
Director/Board Member bij HH&L ACQUISITION CO.
Vermogen: 7 M $ op 29-02-2024
Profiel
Jing Wu Zang, oprichter van I-Mab en I-Mab Biopharma (Shanghai) Co., Ltd., is voorzitter bij I-Mab en voorzitter & Chief Executive Officer van I-Mab Biopharma (Shanghai) Co., Ltd. (een dochteronderneming van I-Mab). (een dochteronderneming van I-Mab). Dr. Zang zit ook in de raad van bestuur van HH&L Acquisition Co. In zijn vorige carrière was Dr. Zang President & Chief Scientific Officer bij Simcere Pharmaceutical Group Ltd., President & Chief Scientific Officer bij BioSciKin Co, Ltd., Directeur-Shanghai Institute of Immunology aan de Shanghai Jiaotong University School of Medicine, Senior VP, Head-Research & Development bij Glaxosmithkline China Ltd., Principal bij Opexa Pharmaceuticals, Inc. en Professor aan het Baylor College of Medicine. Jing Wu Zang behaalde een doctoraat aan de Shanghai Jiao Tong University en een doctoraat aan de Vrije Universiteit Brussel.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
I-MAB
4.98% | 31-12-2023 | 9 449 021 ( 4.98% ) | 7 M $ | 29-02-2024 |
Actieve functies van Jingwu Zhang Zang
Bedrijven | Functie | Begin |
---|---|---|
HH&L ACQUISITION CO. | Director/Board Member | 04-02-2021 |
I-MAB Biopharma Co., Ltd.
I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Founder | 01-06-2016 |
Eerdere bekende functies van Jingwu Zhang Zang
Bedrijven | Functie | Einde |
---|---|---|
I-MAB | Chief Executive Officer | 30-09-2022 |
SIMCERE PHARMACEUTICAL GROUP LIMITED | President | 01-04-2016 |
BioSciKin Co., Ltd.
BioSciKin Co., Ltd. Pharmaceuticals: MajorHealth Technology BioSciKin Co., Ltd. develops drugs and medical products. The private company is based in Nanjing, China. | President | 01-04-2016 |
Glaxosmithkline China Ltd. | Chief Tech/Sci/R&D Officer | 01-06-2013 |
Shanghai Jiao Tong University School of Medicine | Corporate Officer/Principal | 01-04-2007 |
Opleiding van Jingwu Zhang Zang
Shanghai Jiao Tong University | Doctorate Degree |
Vrije Universiteit Brussel | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
SIMCERE PHARMACEUTICAL GROUP LIMITED | Health Technology |
I-MAB | Health Technology |
Bedrijven in privébezit | 7 |
---|---|
Opexa Pharmaceuticals, Inc. | Health Technology |
Institut Pasteur de Shanghai
Institut Pasteur de Shanghai Miscellaneous Commercial ServicesCommercial Services Institut Pasteur de Shanghai operates as a non-profit life sciences organization. The private company is based in Shanghai, China. | Commercial Services |
Glaxosmithkline China Ltd. | |
The Institute of Health Sciences | |
BioSciKin Co., Ltd.
BioSciKin Co., Ltd. Pharmaceuticals: MajorHealth Technology BioSciKin Co., Ltd. develops drugs and medical products. The private company is based in Nanjing, China. | Health Technology |
I-MAB Biopharma Co., Ltd.
I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Health Technology |
HH&L Acquisition Co.
HH&L Acquisition Co. Financial ConglomeratesFinance HH&L Acquisition Co. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on September 4, 2020 and is headquartered in Hong Kong. | Finance |